Chelation therapy saves life of young cardiac patient

5 Dariya News

New Delhi 22-May-2015

A 22-year-old man, who despite two stents in his heart's arteries, developed chest pain, successfully underwent chelation therapy at a hospital here, doctors said on Friday.Life was running fairly smoothly for Kamaljit Singh, a goldsmith, after he had two stents installed in his arteries. A sudden and major chest pain, however, compelled him to see a cardiac expert and he was told to undergo a heart bypass.Worried about post-bypass surgery complications, Singh consulted several other health experts who suggested him to opt for Chelation therapy.Chelation therapy is a chemical process in which a synthetic solution --ethylenediaminetetraacetic acid -- is injected into the bloodstream to remove heavy metals and/or minerals from the body.As part of the therapy at Sibia Medical Centre, Singh underwent 30 treatment sessions, that helped him regain normalcy in health.According to the doctors, formation of blood clots, after stents are implanted in patients, lead to heart attacks and sudden death. Cardiologists for long have pondered what action to take in such situations, and now Chelation therapy has proven to be the perfect solution.

A study showed cardiovascular patients treated with Chelation therapy had a lower rate of myocardial infarction and death, than those treated with medications, angioplasty or heart bypass."In addition to Chelation therapy, cardiovascular rehabilitation programme should include aggressive lifestyle change for all heart patients with or without angioplasty, stents or bypass surgery," said S.S. Sibia, director of Institute of Preventive Heart Care and consultant at Sibia Medical Centre.As per the protocol of Chelation therapy, the dose adjustment is based on kidney function and other parameters, and is administered intravenously once or twice per week for 20-30 sessions."For maintenance, treatments are administered monthly because new platelets are formed approximately every 3.5 weeks. Monthly treatments provide continued platelet aggregation inhibition."